Visgenx develops therapeutics to protect against the loss of sight from retinal disorders.
Visgenx has raised $2.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Visgenx's investors include TCA Venture Group.
Visgenx is headquartered in San Diego, United States.
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders.
Visgenx is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Visgenx — Funding & Investors." VCBacked, June 14, 2023, https://www.vcbacked.co/company/visgenx. Accessed August 15, 2026.
VCBacked. (2023). Visgenx — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/visgenx
{{cite web |title=Visgenx — Funding & Investors |url=https://www.vcbacked.co/company/visgenx |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated